mRNA Bioanalysis Service
Overview
The rapid advancement of messenger RNA (mRNA) technologies has revolutionized the landscape of modern medicine, moving far beyond the initial success of prophylactic vaccines into the realms of oncology and personalized gene therapy. As part of our therapeutic nucleic acid development platform, CD BioGlyco offers a specialized mRNA bioanalysis service designed to bridge the gap between initial mRNA-based vaccine development and successful clinical outcomes.
Effective mRNA therapeutics require rigorous characterization to ensure the stability of the genetic payload, the efficiency of the lipid nanoparticle (LNP) delivery system, and the robustness of the resulting immune response. Our bioanalytical platform provides high-sensitivity quantification and functional assessment of mRNA molecules and their expressed proteins within complex biological matrices. By integrating state-of-the-art molecular biology and immunology techniques, we help researchers navigate the complexities of pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity, ensuring that every candidate meets the highest standards of safety and efficacy.
Key Technologies
- Droplet Digital PCR (ddPCR)
We employ ddPCR for the absolute quantification of mRNA molecules. Unlike traditional methods, ddPCR provides unparalleled sensitivity and precision by partitioning samples into thousands of droplets, allowing for the detection of low-abundance transcripts without the need for standard curves. - Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
Our LC-MS/MS platform is essential for characterizing both the mRNA integrity and the LNP components. This technology allows us to monitor the chemical stability of the mRNA and the metabolic profile of delivery lipids in vivo. - Multiplex Immunoassays
Utilizing platforms like specialized enzyme-linked immunosorbent assays (ELISA), we simultaneously quantify multiple cytokines and biomarkers, providing a comprehensive view of the cellular and humoral immune landscape.
Empowering mRNA Innovation through Precision Bioanalysis
At CD BioGlyco, we provide a specialized suite of services under our therapeutic nucleic acid development platform, specifically tailored for mRNA-based vaccine development. Our mRNA bioanalysis service includes:
-
mRNA Biodistribution Analysis Service
Understanding where mRNA travels and persists within the body is critical for safety and efficacy. We utilize RNA in situ hybridization (ISH) and bioluminescence imaging (BLI) to track the localization of mRNA and its LNP carriers. Our service includes tissue-level quantification across various organs (liver, spleen, lymph nodes) to correlate delivery efficiency with therapeutic outcomes.

-
Cell Cytokine Secretion Analysis Service
Cellular immunity is a cornerstone of mRNA vaccine success. We offer detailed T cell profiling using intracellular cytokine staining (ICS) via flow cytometry. By measuring the secretion of key markers such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α), we evaluate the magnitude and quality of the antigen-specific T cell response.

-
Antibody Titer and Specificity Analysis Service
Quantifying the humoral immune response is essential for assessing vaccine potency. Our team develops highly sensitive enzyme-linked immunosorbent assays (ELISA) and surface plasmon resonance (SPR) protocols to measure total antibody titers and binding kinetics. We also analyze antibody specificity to ensure the response is targeted precisely toward the encoded antigen, minimizing off-target reactivity.

-
Neutralizing Antibody Assay Service
The ultimate measure of vaccine efficacy is the production of neutralizing antibodies (nAbs). We provide functional assays, including pseudovirus neutralization tests (pVNT) and live virus microneutralization assays, to determine the ability of vaccine-induced antibodies to block viral entry. These assays are essential for establishing correlates of protection in preclinical studies.

Workflow
Consultation and Strategy Design
We collaborate with you to define the study objectives, selecting the most appropriate biomarkers and analytical methods based on your specific mRNA construct and target disease.
Sample Preparation and Processing
Whether working with serum, tissues, or purified mRNA, our team implements standardized protocols for sample extraction and stabilization to prevent RNA degradation and ensure data reproducibility.
Assay Development and Optimization
Our scientists develop custom assays or adapt platform methods to suit your unique antigen. This stage includes meticulous validation of sensitivity, specificity, and dynamic range.
High-Throughput Execution
Utilizing automated liquid handling and advanced detection systems, we process samples efficiently, maintaining high precision even for large-scale samples.
Advanced Bioinformatic Analysis
Raw data is processed using proprietary bioinformatic pipelines to extract meaningful insights, such as cytokine polyfunctionality indexes or antibody maturation trends.
Quality Validation and Reporting
Every project undergoes a multi-step quality control (QC) review. We provide a comprehensive final report containing detailed methodology, raw data, and expert interpretation.
Applications
Infectious Disease Vaccines
Our services accelerate the development of mRNA vaccines against viral and bacterial pathogens by providing rapid immunogenicity readouts and efficacy data in both preclinical models and proclinical samples.
Cancer Immunotherapy
We support the characterization of neoantigen-based cancer vaccines, evaluating the ability of mRNA to induce potent, tumor-specific T cell responses and long-term immune memory in complex oncology environments.
Protein Replacement Therapy
For non-vaccine applications, we monitor the expression levels and biodistribution of mRNA-encoded functional proteins, ensuring that therapeutic thresholds are met in target tissues such as the liver or lungs.
Gene Editing Support
We provide critical bioanalytical data for mRNA-delivered gene editing systems, tracking the transient expression of nucleases and assessing any potential innate immune triggers caused by the delivery vehicle or mRNA sequence.
Advantages
Exceptional Sensitivity and Precision
CD BioGlyco employs state-of-the-art detection technologies that provide low limits of detection (LOD), ensuring that even trace amounts of mRNA or low-titer antibody responses are accurately quantified and characterized.
Comprehensive Integrated Services
We offer an "all-in-one" solution that covers everything from structural integrity testing to functional immunological assays, reducing the need for multiple vendors and streamlining the entire development timeline for our clients.
Rigorous Quality Management
Our bioanalytical services are conducted following rigorous quality management systems, providing data that is suitable for preclinical research.
Highly Customizable Assays
Recognizing that every mRNA project is unique, we provide tailored assay development services that adapt to specific delivery systems, target antigens, and animal models, ensuring maximum relevance of the generated data.
Frequently Asked Questions
Customer Review
Their team's ability to correlate mRNA localization with protein expression gave us the confidence we needed to move forward. The technical support was exceptional throughout the project.
— C.T., Director of Bioanalysis
CD BioGlyco managed to detect subtle immune shifts in our low-dose groups that other labs missed. Their workflow is efficient, and the final reports are of the highest quality.
— B.E., Senior Scientist
Partnering with CD BioGlyco for our neutralizing antibody assays saved us months of internal development. The data was highly reproducible across different batches. We look forward to our next collaboration.
— C.S., Head of Immunology
Associated Services
CD BioGlyco is your dedicated partner for comprehensive and high-precision mRNA bioanalysis service. From initial structural characterization to complex immunogenicity profiling, we provide the scientific expertise and advanced technology required to bring your mRNA therapeutics to life. Please feel free to contact us for detailed information on our services or to request a formal quotation.
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform